Switzerland· 44157001
kodan forte farblos, Lösung zur Anwendung auf der Haut
A biphenylol product, registered in Switzerland by Schülke & Mayr AG and dispensed under Swissmedic category D.
Checked against the register on
Informational only — not a medical device.
The record
At a glance
- Manufacturer
- Schülke & Mayr AG
- Country
- Switzerland (CH)
- ATC code
- D08AE06
- ATC class
- Biphenylol
- Swissmedic category
- D
- Reimbursed
- No
- Last checked
- June 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under D08AE06
Biphenylol, as other registers publish it.
- Switzerlandkodan forte farblos, Lösung zur Anwendung auf der HautSchülke & Mayr AG
- Switzerlandkodan forte farblos, Lösung zur Anwendung auf der HautSchülke & Mayr AG
- Switzerlandkodan forte farblos, Lösung zur Anwendung auf der HautSchülke & Mayr AG
- Switzerlandkodan forte farblos, Lösung zur Anwendung auf der HautSchülke & Mayr AG
- Switzerlandkodan forte gefärbt, Lösung zur Anwendung auf der HautSchülke & Mayr AG
- Switzerlandkodan forte gefärbt, Lösung zur Anwendung auf der HautSchülke & Mayr AG
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b6042553-2cb9-4344-b5d4-ca45763afa43 GET /v1/drugs/b6042553-2cb9-4344-b5d4-ca45763afa43?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "swissmedic_auth",
"heilmittelcode": "Synthetika"
}See everything about biphenylol.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.